scholarly journals Removing melatonin receptor type 1 signaling leads to selective leptin resistance in the arcuate nucleus

2019 ◽  
Vol 67 (2) ◽  
Author(s):  
Daniella Buonfiglio ◽  
Cynthia Tchio ◽  
Isadora Furigo ◽  
José Donato ◽  
Kenkichi Baba ◽  
...  
Keyword(s):  
Arcuate Nucleus ◽  
Receptor Type ◽  
Leptin Resistance ◽  
Melatonin Receptor

Melatonin Receptor Type 1 Signals to Extracellular Signal-Regulated Kinase 1 and 2 via Giand GsDually Coupled Pathways in HEK-293 Cells

Biochemistry ◽  
2014 ◽  
Vol 53 (17) ◽  
pp. 2827-2839 ◽  
Author(s):  
Linjie Chen ◽  
Xiaobai He ◽  
Yaping Zhang ◽  
Xiaopan Chen ◽  
Xiangru Lai ◽  
...  
Keyword(s):  
Receptor Type ◽  
Melatonin Receptor ◽  
Hek 293 ◽  
Extracellular Signal Regulated Kinase ◽  
Hek 293 Cells ◽  
293 Cells ◽  
Extracellular Signal

scholarly journals Nocturnal activation of melatonin receptor type 1 signaling modulates diurnal insulin sensitivity via regulation of PI3K activity

2018 ◽  
Vol 64 (3) ◽  
pp. e12462 ◽  
Author(s):  
Sharon Owino ◽  
Aida Sánchez-Bretaño ◽  
Cynthia Tchio ◽  
Erika Cecon ◽  
Angeliki Karamitri ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Receptor Type ◽  
Melatonin Receptor ◽  
Pi3k Activity

scholarly journals Removal of Melatonin Receptor Type 1 Induces Insulin Resistance in the Mouse

Obesity ◽  
2010 ◽  
Vol 18 (9) ◽  
pp. 1861-1863 ◽  
Author(s):  
Susana Contreras-Alcantara ◽  
Kenkichi Baba ◽  
Gianluca Tosini
Keyword(s):  
Insulin Resistance ◽  
Receptor Type ◽  
Melatonin Receptor

Melatonin Receptor as a Drug Target for Neuroprotection

2020 ◽  
Vol 14 (2) ◽  
pp. 150-164 ◽  
Author(s):  
Pawaris Wongprayoon ◽  
Piyarat Govitrapong
Keyword(s):  
The Body ◽  
Melatonin Receptors ◽  
Receptor Type ◽  
Substantia Nigra Pars Compacta ◽  
Melatonin Receptor ◽  
Amyloid Aβ ◽  
Disease Modifying Agents ◽  
Cerebral Ischemic ◽  
Cerebral Ischemic Reperfusion

Background:: Melatonin, a neurohormone secreted from the pineal gland, circulates throughout the body and then mediates several physiological functions. The pharmacological effects of melatonin can be mediated through its direct antioxidant activity and receptor-dependent signaling. Objective: This article will mainly review receptor-dependent signaling. Human melatonin receptors include melatonin receptor type 1 (MT1) and melatonin receptor type 2 (MT2), which are widely distributed throughout the brain. Result: Several lines of evidence have revealed the involvement of the melatonergic system in different neurodegenerative diseases. Alzheimer’s disease pathology negatively affects the melatonergic system. Melatonin effectively inhibits β-amyloid (Aβ) synthesis and fibril formation. These effects are reversed by pharmacological melatonin receptor blockade. Reductions in MT1 and MT2 expression in the amygdala and substantia nigra pars compacta have been reported in Parkinson’s disease patients. The protective roles of melatonin against ischemic insults via its receptors have also been demonstrated. Melatonin has been reported to enhance neurogenesis through MT2 activation in cerebral ischemic/reperfusion mice. The neurogenic effects of melatonin on mesenchymal stem cells are particularly mediated through MT2. Conclusion: Understanding the roles of melatonin receptors in neuroprotection against diseases may lead to the development of specific analogs with specificity and potency greater than those of the original compound. These successfully developed compounds may serve as candidate preventive and disease-modifying agents in the future.

scholarly journals Is the Melatonin Receptor Type 1 Involved in the Pathogenesis of Glaucoma?

2013 ◽  
Vol 22 ◽  
pp. S49-S50 ◽  
Author(s):  
Gianluca Tosini ◽  
Jeffrey H. Boatright
Keyword(s):  
Receptor Type ◽  
Melatonin Receptor
Sign in / Sign up

Export Citation Format

Share Document